<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522064</url>
  </required_header>
  <id_info>
    <org_study_id>HiTECH</org_study_id>
    <nct_id>NCT03522064</nct_id>
  </id_info>
  <brief_title>Bipolar Androgen Therapy + Carboplatin in mCRPC</brief_title>
  <acronym>HiTeCH</acronym>
  <official_title>High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of BAT and carboplatin in men with&#xD;
      metastatic castrate-resistant prostate cancer (mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen deprivation therapy (ADT) remains the mainstay of prostate cancer treatment. Though&#xD;
      an effective therapy initially, the side effects of ADT are numerous and treatment resistance&#xD;
      is inevitable. Castrate-refractory prostate cancer (CRPC) progresses via adaptive mechanisms&#xD;
      that allow ongoing androgen receptor (AR) signalling despite castrate levels of androgens.&#xD;
&#xD;
      The concept of cycling between supra- and sub physiological levels of testosterone has been&#xD;
      tested recently in studies of &quot;bipolar androgen therapy&quot; (BAT) in which patients are given&#xD;
      high dose testosterone in combination with androgen deprivation therapy (ADT) via an LHRH&#xD;
      agonist/antagonist. Studies of BAT using IM testosterone have been promising both in terms of&#xD;
      PSA responses and quality of life improvements. Additionally, these early phase studies&#xD;
      suggest the potential for re-sensitisation to novel anti-androgen therapies.&#xD;
&#xD;
      Though responses have been positive in these early studies a proportion of men fail to&#xD;
      respond and data to guide patient selection is lacking. There are data to suggest that&#xD;
      patients with DNA repair deficits may be particularly responsive to BAT. Whether these&#xD;
      changes serve as predictors of response is unknown as the effect of BAT on the tumour, its&#xD;
      microenvironment and peripheral circulating tumour DNA has not been studied in detail.&#xD;
      Information on treatment effects may be key to appropriate patient selection for this&#xD;
      treatment.&#xD;
&#xD;
      The aim of this study is to assess based on the pre-clinical studies, the combination with&#xD;
      carboplatin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>&gt;/= 50% fall from baseline PSA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>1 year</time_frame>
    <description>Time to increase in PSA &gt;/=25% from baseline or nadir confirmed on subsequent test &gt;1 week later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>RECIST or PCWG3 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (Frequency of adverse events as assessed by NCI CTCAE v4.0)</measure>
    <time_frame>1 year</time_frame>
    <description>Frequency of adverse events as assessed by NCI CTCAE v4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in ctDNA expression from baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum testosterone and oestradiol levels</measure>
    <time_frame>1 year</time_frame>
    <description>Change in serum levels from baseline to Days 14 and 28 of cycle 1</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Homologous Recombination Deficiency</condition>
  <arm_group>
    <arm_group_label>High dose testosterone + Carbolplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate 100 MG/ML Injectable Solution</intervention_name>
    <description>Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.</description>
    <arm_group_label>High dose testosterone + Carbolplatin</arm_group_label>
    <other_name>Primoteston Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5</intervention_name>
    <description>Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures</description>
    <arm_group_label>High dose testosterone + Carbolplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males with histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          2. Confirmed HRD (Homologous recombination defect) in germline and/or somatic DNA&#xD;
             analysis (tumour or blood), by a validated assay (see Appendix 1). Mutations in HR&#xD;
             genes not listed in appendix 1 will be considered in literature suggests&#xD;
             pathogenicity. A maximum of 10 uncharacterised or heterozygous mutations will be&#xD;
             included.&#xD;
&#xD;
          3. Age ≥ 18 years&#xD;
&#xD;
          4. ECOG performance status ≤ 1&#xD;
&#xD;
          5. Rising PSA confirmed on two sequential tests ≥1 week apart and a minimum value of 2&#xD;
             ug/L despite castrate levels of testosterone&#xD;
&#xD;
          6. Serum testosterone &lt; 1.7 nmol/L and on an LHRH agent or post orchidectomy ≥ 1 year.&#xD;
&#xD;
          7. Washout of ≥ 4 weeks from prior line of treatment, radiotherapy or surgery (aside from&#xD;
             LHRH agent)&#xD;
&#xD;
          8. Adequate bone marrow function (platelets &gt; 100 x 109/L, ANC &gt; 1.5 x 109/L, Hb &gt;100)&#xD;
&#xD;
          9. Adequate liver function (ALT/AST &lt; 1.5 x ULN, bilirubin &lt; 2 x ULN)&#xD;
&#xD;
         10. Adequate renal function (creatinine clearance &gt; 50 ml/min)&#xD;
&#xD;
         11. Adequate cardiac function and reserve after cardiology assessment&#xD;
&#xD;
         12. Archived tissue sample available or willingness to undergo fresh biopsy&#xD;
&#xD;
         13. Willing and able to comply with all study requirements, including treatment, timing&#xD;
             and/or nature of required assessments&#xD;
&#xD;
         14. Signed, written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to investigational product&#xD;
&#xD;
          2. Pain due to metastatic prostate cancer requiring opioid analgesics&#xD;
&#xD;
          3. Evidence of disease progression in sites or extent that, in the opinion of the&#xD;
             investigator, would put the patient at risk from testosterone therapy and its&#xD;
             potential for initial tumour flare (eg: femoral metastasis at risk of fracture,&#xD;
             ureteric obstruction due to nodal disease or cord compression due to spinal&#xD;
             metastases).&#xD;
&#xD;
          4. Previous treatment with platinum chemotherapy and/or a PARP inhibitor. However up to 8&#xD;
             men with prior treatment to these agents will be included as an exploratory cohort.&#xD;
&#xD;
          5. Life expectancy of less than 3 months.&#xD;
&#xD;
          6. Brain metastases or leptomeningeal disease&#xD;
&#xD;
          7. History of thromboembolic event and not currently on anticoagulation&#xD;
&#xD;
          8. Prior myocardial infarction or unstable angina within 2 years of study entry&#xD;
&#xD;
          9. Haematocrit ≥ 50%, untreated severe obstructive sleep apnoea or poorly controlled&#xD;
             heart failure (NYHA &gt;1)&#xD;
&#xD;
         10. History of another malignancy within 5 years prior to registration. Patients with a&#xD;
             past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the&#xD;
             skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma&#xD;
             of the bladder are eligible. Patients with a history of other malignancies are&#xD;
             eligible if they have been continuously disease free for at least 5 years after&#xD;
             definitive primary treatment.&#xD;
&#xD;
         11. Concurrent illness, including severe infection that may jeopardize the ability of the&#xD;
             patient to undergo the procedures outlined in this protocol with reasonable safety.&#xD;
&#xD;
         12. Presence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule,&#xD;
             including alcohol dependence or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony M Joshua, MBBS, PhD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's Hospital-Manhattan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Kent</last_name>
    <phone>+61293555611</phone>
    <email>SVHS.CancerResearch@svha.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre, St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
      <phone>0293555611</phone>
      <email>SVHS.CancerResearch@svha.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.</citation>
    <PMID>29248236</PMID>
  </reference>
  <reference>
    <citation>Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.</citation>
    <PMID>27338150</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Anthony Joshua, FRACP</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Castrate-resistant prostate cancer</keyword>
  <keyword>bipolar androgen therapy</keyword>
  <keyword>homologous recombination deficiency</keyword>
  <keyword>BRCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

